评论：脊髓性肌萎缩症基因治疗的现状 - Suppr

Suppr

超能文献

Commentary: Current Status of Gene Therapy for Spinal Muscular Atrophy.

作者信息

Rossoll Wilfried, Singh Ravindra N

机构信息

Department of Neuroscience, Mayo Clinic, Jacksonville, FL, United States.

Department of Biomedical Sciences, Iowa State University, Ames, IA, United States.

出版信息

Front Cell Neurosci. 2022 May 17;16:916065. doi: 10.3389/fncel.2022.916065. eCollection 2022.

DOI:10.3389/fncel.2022.916065

PMID:35656408

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9152110/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46c9/9152110/c0db78941728/fncel-16-916065-g0001.jpg

相似文献

Commentary: Current Status of Gene Therapy for Spinal Muscular Atrophy.评论：脊髓性肌萎缩症基因治疗的现状

Front Cell Neurosci. 2022 May 17;16:916065. doi: 10.3389/fncel.2022.916065. eCollection 2022.

Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma).脊髓性肌萎缩症（SMA）的基因治疗：关于onasemnogene abeparvovec（Zolgensma）的当前挑战和安全性考量的综述

Cureus. 2023 Mar 15;15(3):e36197. doi: 10.7759/cureus.36197. eCollection 2023 Mar.

[Pharmacological and clinical profile of Onasemnogene Aveparvovec, the first gene therapy for spinal muscular atrophy (SMA)].首个用于脊髓性肌萎缩症（SMA）的基因疗法——onasemnogene aveparvovec的药理及临床概况

Nihon Yakurigaku Zasshi. 2022;157(1):53-61. doi: 10.1254/fpj.21066.

From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1.从临床试验到临床实践：SMA 类型 1 基因替代治疗的实际考虑因素。

Pediatr Neurol. 2019 Nov;100:3-11. doi: 10.1016/j.pediatrneurol.2019.06.007. Epub 2019 Jun 13.

Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular Atrophy.onasemnogene abeparvovec（AVXS-101）用于治疗脊髓性肌萎缩症。

J Pediatr Pharmacol Ther. 2021;26(5):437-444. doi: 10.5863/1551-6776-26.5.437. Epub 2021 Jun 28.

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.依洛硫酸酯酶 n 注射液治疗携带 2 个 SMN2 拷贝的脊髓性肌萎缩症婴儿起病型患者的症状：一项开放标签、单臂、多中心、3 期临床试验。

Lancet Neurol. 2021 Apr;20(4):284-293. doi: 10.1016/S1474-4422(21)00001-6. Epub 2021 Mar 17.

Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy.Onasemnogene Abeparvovec-xioi：脊髓性肌萎缩症的基因治疗。

Ann Pharmacother. 2020 Oct;54(10):1001-1009. doi: 10.1177/1060028020914274. Epub 2020 Mar 23.

Onasemnogene Abeparvovec: First Global Approval.Onasemnogene Abeparvovec：全球首次获批。

Drugs. 2019 Jul;79(11):1255-1262. doi: 10.1007/s40265-019-01162-5.

Onasemnogene abeparvovec for the treatment of spinal muscular atrophy.依洛硫酸酯酶 n 注射液治疗脊髓性肌萎缩症。

Expert Opin Biol Ther. 2022 Sep;22(9):1075-1090. doi: 10.1080/14712598.2022.2066471. Epub 2022 May 2.

Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios.荷兰脊髓性肌萎缩症 I 患者使用 Onasemnogene Abeparvovec-xioi（Zolgensma）和 Nusinersen（Spinraza）治疗的早期成本效益：考虑复发情景

Value Health. 2021 Jun;24(6):759-769. doi: 10.1016/j.jval.2020.09.021. Epub 2021 Mar 31.

引用本文的文献

Rewriting nuclear epigenetic scripts in mitochondrial diseases as a strategy for heteroplasmy control.改写线粒体疾病中的核表观遗传脚本作为异质性控制策略。

EMBO Mol Med. 2025 Aug 11. doi: 10.1038/s44321-025-00285-5.

Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects.脂质体和脂质纳米颗粒在癌症治疗中的应用：当前进展与展望

Exp Hematol Oncol. 2025 Jan 31;14(1):11. doi: 10.1186/s40164-025-00602-1.

Clinical perspectives: Treating spinal muscular atrophy.临床视角：脊髓性肌萎缩症的治疗

Mol Ther. 2024 Aug 7;32(8):2489-2504. doi: 10.1016/j.ymthe.2024.06.020. Epub 2024 Jun 18.

Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy.针对脊髓性肌萎缩症的 SMN2 靶向剪接调节小分子治疗的多样化靶点。

Nucleic Acids Res. 2023 Jul 7;51(12):5948-5980. doi: 10.1093/nar/gkad259.

本文引用的文献

Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.用onasemnogene abeparvovec 基因替换疗法治疗年龄在 24 个月或以下且体重不超过 15 公斤的脊髓性肌萎缩症儿童：一项观察性队列研究。

Lancet Child Adolesc Health. 2022 Jan;6(1):17-27. doi: 10.1016/S2352-4642(21)00287-X. Epub 2021 Oct 29.

A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases.一种优化腺相关病毒向脑部递送以治疗神经退行性疾病的多方面方法。

Front Neurosci. 2021 Sep 24;15:747726. doi: 10.3389/fnins.2021.747726. eCollection 2021.

Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.onasemnogene abeparvovec DNA、mRNA 和 SMN 蛋白在人体组织中的分布。

Nat Med. 2021 Oct;27(10):1701-1711. doi: 10.1038/s41591-021-01483-7. Epub 2021 Oct 4.

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.针对 1 型脊髓性肌萎缩症（SMA）的婴儿期起病症状性的 Onasemnogene abeparvovec 基因治疗（STR1VE-EU）：一项开放标签、单臂、多中心、3 期临床试验。

Lancet Neurol. 2021 Oct;20(10):832-841. doi: 10.1016/S1474-4422(21)00251-9.

SMN protein is required throughout life to prevent spinal muscular atrophy disease progression.存活期内需要 SMN 蛋白以防止脊髓性肌肉萎缩症进展。

Hum Mol Genet. 2021 Dec 17;31(1):82-96. doi: 10.1093/hmg/ddab220.

Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit.长期 AAV9 介导的 SMN 过表达在感觉运动回路中获得毒性功能。

Nat Neurosci. 2021 Jul;24(7):930-940. doi: 10.1038/s41593-021-00827-3. Epub 2021 Apr 1.

Lancet Neurol. 2021 Apr;20(4):284-293. doi: 10.1016/S1474-4422(21)00001-6. Epub 2021 Mar 17.

Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.脊髓性肌萎缩症：广泛的疾病谱和性别特异性表型。

Biochim Biophys Acta Mol Basis Dis. 2021 Apr 1;1867(4):166063. doi: 10.1016/j.bbadis.2020.166063. Epub 2021 Jan 5.

The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy.首款用于治疗脊髓性肌萎缩症的口服小分子药物。

Neurosci Insights. 2020 Nov 23;15:2633105520973985. doi: 10.1177/2633105520973985. eCollection 2020.

MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates.微小 RNA 介导的转基因表达抑制可减少灵长类动物 AAV 载体引起的背根神经节毒性。

Sci Transl Med. 2020 Nov 11;12(569). doi: 10.1126/scitranslmed.aba9188.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验